Recombinant filovirus rescue transfections

AH Adam J. Hume
BH Baylee Heiden
JO Judith Olejnik
ES Ellen L. Suder
SR Stephen Ross
WS Whitney A. Scoon
EB Esther Bullitt
ME Maria Ericsson
MW Mitchell R. White
JT Jacquelyn Turcinovic
TT Tran T. N. Thao
RH Ryan M. Hekman
JK Joseph E. Kaserman
JH Jessie Huang
KA Konstantinos-Dionysios Alysandratos
GT Gabor E. Toth
FJ Ferenc Jakab
DK Darrell N. Kotton
AW Andrew A. Wilson
AE Andrew Emili
VT Volker Thiel
JC John H. Connor
GK Gabor Kemenesi
DC Daniel Cifuentes
EM Elke Mühlberger
request Request a Protocol
ask Ask a question
Favorite

Recombinant LLOV rescue transfections were performed similar to rescue transfections for other filoviruses Briefly, 1:1 mixtures of Huh7:Vero E6 cells (1x105 cells plated per well of a 12-well plate) were transfected with LLOV support plasmids (500 ng pCAGGS-NPLLOV, 125 ng pCAGGS-VP35LLOV, 50 ng pCAGGS-VP30LLOV, and 200 ng pCAGGS-LLLOV), pCAGGS-T7 (50 ng; codon-optimized), and a full-length plasmid containing the chimeric LLOV genome (1 μg) using TransIT-LT1 per manufacturer’s recommendations (Mirus Bio LLC). Media was changed approximately 18 hours post-transfection and cells were monitored for cytopathic effect (CPE) and fluorescence for ZsGreen-containing clones. Supernatants of cells showing CPE and/or fluorescence were transferred to T75 flasks of Vero E6 cells approximately 7–11 days post-transfection. rEBOV-ZsGreen and rRESTV-ZsGreen clones were rescued similarly, using the corresponding full-length plasmids (1 μg each), pCAGGS-T7 (50 ng; codon-optimized), plus the EBOV (750 ng pCAGGS-NPEBOV, 125 ng pCAGGS-VP35EBOV, 50 ng pCAGGS-VP30EBOV, and 100 ng pCAGGS-LEBOV) or RESTV (350 ng pCAGGS-NPRESTV, 125 ng pCAGGS-VP35RESTV, 50 ng pCAGGS-VP30RESTV, and 350 ng pCAGGS-LRESTV) support plasmids, respectively. Rescue of recombinant filoviruses, including LLOV, was performed in BSL-4 facility of the NEIDL following BSL-4 biosafety procedures.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A